Implementation Science to Improve the Diagnosis and Management of Hidradenitis Suppurativa: HELyx Study Design Overview
The primary endpoint is the change in the proportion of HCPs who used a diagnostic screening tool to identify patients with suspected HS during the 24 weeks of the post-implementation phase (assessed at Week 24) compared to the 24 weeks before implementation (assessed at baseline). Secondary endpoints include assessment of the use of HS disease severity assessment and patient-reported outcome tools and HCP referral behaviours.
Authors
- Mona Biermann (ORCID: https://orcid.org/0000-0003-0496-5988)
- John R Ingram (ORCID: https://orcid.org/0000-0002-5257-1142)
- Antonio Martorell (ORCID: https://orcid.org/0000-0003-1378-1590)
- Yvonne Geissbühler (ORCID: https://orcid.org/0000-0001-8528-6818)
- Falk G. Bechara (ORCID: https://orcid.org/0000-0003-0418-521X)
- Erhard Quebe‐Fehling (ORCID: https://orcid.org/0000-0003-1507-9543)
- Michael A. Fritz
- Marco Romanelli (ORCID: https://orcid.org/0000-0002-4127-0141)
- Craig Richardson
- Maria Zahid (ORCID: https://orcid.org/0000-0001-8445-2503)
- Barry M. McGrath (ORCID: https://orcid.org/0000-0001-6995-7714)
- Pierre‐André Bécherel
- Georgios Kokolakis
- Benjamin M. Haeberle
Institutions
- University of Pisa (IT)
- Novartis (Switzerland) (CH)
- University Hospitals of the Ruhr-University of Bochum (DE)
- Humboldt-Universität zu Berlin (DE)
- Novartis (Germany) (DE)
- Hospital de Manises (ES)
- Charité - Universitätsmedizin Berlin (DE)
- Cardiff University (GB)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1007/s13555-025-01350-0
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis
- Novartis Pharma